Welche Marker helfen bei der Therapiewahl?

Zur Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) haben Ärzte in Deutschland mit Docetaxel, Cabazitaxel, Abirateron, Enzalutamid und Radium-223 verschiedene Optionen zur Verfügung. Klinische Marker, die bei der Therapiewahl helfen könnten, sind bisher nicht ausreichend validiert. Mit aktuellen Erkenntnissen zu neuen Biomarkern beschäftigte sich ein Symposium auf dem DGHO 2017.

• Literatur

• 1 Droz JP. et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15 (09) e404-e414.
• 2 Gillessen S. et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017 Vorabpublikation, doi: 10.1016/j.eururo.2017.06.002
• 3 Oudard S. et al. Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017 Vorabpublikation, doi: 10.1200/JCO.2016.72
• 4 Fitzpatrick JM. et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50 (09) 1617-1627.
• 5 Fizazi K. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. NEJM 2017; 377 (04) 352-360.
• 6 Antonorakis ES. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. NEJM 2014; 371 (11) 1028-1038.
• 7 Antonorakis ES. et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With Firstand Second-Line Abiraterone and Enzalutamide. . J Clin Oncol 2017; 35 (19) 2149-2156.
• 8 Robinson D. et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015; 161: 1215-1228.
• 9 Ross JS. et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9(17): 6357–6362Fendler WP et al: 68Ga-PSMA-11 PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44: 1014-1024.